Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aficamten shows promise for thick heart muscle in chinese patients

NCT ID NCT06116968

Disease control Sponsor: Corxel Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called aficamten in 40 Chinese patients with a type of heart disease where the heart muscle is too thick and blocks blood flow. The goal was to see if the drug is safe and helps the heart work better over time. Patients who had already been in a similar study took the drug and were monitored for side effects and heart function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

40 people

The number who actually took part.

Started

Nov 2023

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Completion of a Cytokinetics trial investigating CK-3773274 2. LVEF ≥55% at the Screening Visit Exclusion Criteria: 1. Has participated in another investigational device or drug study or received an investigational device or drug \<1 month (or 5 half-lives for drugs, whichever is longer) prior to screening. Other investigational procedures while participating in this study are not permitted. 2. Since completion of a previous study of aficamten has:Developed new-onset paroxysmal or permanent atrial fibrillation (AF) requiring rhythm restoring treatment (e.g., direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) \<30 days prior to screening. Patient may rescreen for JX01003 after 30 days if heart rate (HR) \<100 bpm and/or rhythm is stable \>30 days. 3. Undergone septal reduction therapy (surgical myectomy or transcatheter alcohol ablation). 4. Had a confirmed LVEF \<40% with an associated dose interruption during participation in a prior study with aficamten. 5. History of appropriate implantable cardioverter defibrillator (ICD) shock within 30 days prior to screening. 6. Has received treatment with mavacamten.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obstructive hypertrophic cardiomyopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obstructive hypertrophic cardiomyopathy

Contacts and locations

Locations

  • Beijing Anzhen Hospital

    Beijing, China

  • Beijing Chao-yang Hospital, Capital Medical University

    Beijing, China

  • Fuwai Hospital, CAMS & PUMC

    Beijing, China

  • Nanfang Hospital

    Guangzhou, China

  • Peking University Third Hospital

    Beijing, China

  • Shengjing Hospital of China Medical University

    Shenyang, China

  • Sichuan Provincial People's Hospital

    Chengdu, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

  • The First Hospital of Jilin University

    Jilin City, China

  • The Second Affiliated Hospital of Nanchang University

    Jiangxi, China

  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.